ER-定位于细胞内的去腺苷酸酶PNLDC1通过靶向TUBB4B的mRNA降解来抑制结肠直肠癌的进展
ER-Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B
Lexin Liu, Yuelin Guan, Yuzhou Qin, Guiping Chen, Guozhen Wang, Xiang Yan, Xue Li, Lei Sun, Wei Yu, Shi Ouyang, Zhichao Ma, Zihao Xu, Zhongkai Cao, Fan Yu, Tong Zhou, Ziyou Luo, Xiangjun Chen, Yongbi
Journal:Exploration
IF:30.4
DOI:10.1002/exp2.70222
PMID:42774471
Published:2026-09-21
research field:肿瘤学分子生物学RNA代谢癌症治疗
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, highlighting the urgent need for novel therapeutic strategies. In this study, we find that PARN-like Domain Containing protein-1 (PNLDC1), an endoplasmic reticulum-localized deadenylase, lower expresses in 91 clinical CRC tissues. Using both in vitro and in vivo models, we identify PNLDC1 as a key tumor suppressor by modulating cell cycle progression in CRC. RNA-immunoprecipitation and sequencing analyses reveal that PNLDC1 binds cell cycle-associated mRNAs, with TUBB4B emerging as a critical target. PNLDC1 downregulates TUBB4B mRNA, whose regulated degradation is essential for PNLDC1's tumor-suppressive function. Restoration of TUBB4B expression counteracts PNLDC1-mediated suppression of CRC cell proliferation, underscoring its pivotal role in CRC pathogenesis. Importantly, we demonstrate that the TUBB4B inhibitor, mebendazole, effectively suppresses the enhanced proliferation in lower-expression PNLDC1 models, including cell, mouse xenografts, and patient-derived tumor-like cell clusters, positioning it as a promising therapeutic agent. These findings establish PNLDC1 as a valuable biomarker and therapeutic target, paving the way for developing novel CRC treatments.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


